Neurology Neuroimmunology & Neuroinflammation· 2026Q1
Antibody-Dependent Cellular Phagocytosis and Cytotoxicity in Patients With LGI1 and CASPR2 Encephalitis
- 0citations
- Q1SCImago
- 2026year
Short summary
The presence of both antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) by LGI1/CASPR2-IgG antibodies predicts a poor long-term outcome (mRS>1) in autoimmune encephalitis patients, with an odds ratio of 10.97.
AI-generated from the title and abstract; the full text is not read.
Key points
- A combined ADCC+/ADCP+ effector function profile of LGI1/CASPR2-IgG antibodies was identified in 28 out of 55 patients.
- Quantitative ADCP levels showed a moderate correlation with LGI1/CASPR2-IgG titer (rho=0.35), while ADCC showed a moderate/strong correlation (rho=0.54).
- Complement-dependent cytotoxicity (CDC) activation was not observed in any patients.
- The ADCC+/ADCP+ profile was the only significant predictor of poor outcome (mRS>1) in a multivariate logistic regression model (OR: 10.97, p=0.014).
AI-generated from the title and abstract; the full text is not read.
Abstract
This database includes the raw data linked with the paper “ Antibody-dependent cellular-phagocytosis and -cytotoxicity in patients with LGI1 and CASPR2 encephalitis”. Objective: Antibodies against LGI1 and CASPR2 (LGI1/CASPR2-IgG) associate with forms of autoimmune encephalitis (AE) that improve with immunotherapy but often show long term neuropsychiatric sequelae. We aimed to investigate autoantibodies effector functions as prognostic biomarkers in patients with LGI1/CASPR2 AE. Methods: We included patients with LGI1/CASPR2 AE, sufficient clinical information and one serum sample available. We assessed the functional profile of LGI1/CASPR2-IgG using in-vitro cell-based assays for complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular-cytotoxicity (ADCC). Outcome was measured using the modified Rankin Scale (mRS) and the Clinical Assessment Scale in AE (CASE). Results: we enrolled 55 patients (LGI1=31, CASPR2=24). Co-existent ADCC and ADCP (ADCC+/ADCP+) were found in 28/55 patients (10/31 with LGI1 and 18/24 with CASPR2), while an isolated ADCP (ADCC-/ ADCP+) was detected in 15 patients (12 with LGI1-IgG and 3 with CASPR2-IgG), and an isolated ADCC (ADCC+/ADCP-) in two LGI1-IgG-positive patients. As most patients (84%) showed a combination of IgG1/IgG3 and IgG4 subclass, no specific functional profiles could be identified according to the predominant subclass. Quantitative ADCP levels showed only a moderate correlation with CASPR2/LGI1-IgG titer (rho=0.35, p=0.02), while ADCC showed a moderate/strong correlation (rho=0.54, p=0.002). None of the patients showed CDC activation. In a multivariate logistic regression model (including functional profile, rituximab treatment, relapsing course and cognitive impairment at onset) the ADCC+/ADCP+ profile was the only predictor of poor outcome (mRS>1, (OR: 10.97 [CI, 1.96–106.9]; p=0.014). Conclusions: ADCC and ADCP, but not CDC, are common effector functions of LGI1/CASPR2-IgG, and their presence correlates with long-term poor outcome, suggesting that they might represent a useful prognostic biomarker. We provide the proof-of-principle for a framework that could be applied to other antibody-mediated conditions of the nervous system.
The authors' abstract, as published at the source. Neurology Neuroimmunology & Neuroinflammation, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Neurology (Medicine)
NeurologyMedicine